Standardization and modification techniques of platelet-rich plasma (PRP) preparation in rabbit

Abstract

Background: Platelet-rich plasma (PRP) is used in several different fields of surgery to enhance natural healing by increasing concentrations of autologous platelets. However, there are controversial arguments in the literature considering the potential benefits of PRP, due to the deficiency of optimized and standardized preparation protocols.

Aim: The aim of the present study is to standardize a method of autologous PRP preparation in rabbits, and also compare this methodology with our new modified method.

Methods: 10 male New Zealand white rabbits were used in this study. After general anesthesia, 10ml of blood was collected from each animal via jugular vein, then the blood was divided into two equal amounts of 5ml. Blood samples were divided into two groups, and two different methods were implemented to prepare PRP. In group one, standardized technique with double centrifugation and in group two, our proposed modified protocol were used to prepare PRP with more than double centrifugation. Platelet count in PRP and whole blood samples with Neubauer slide.

Results: The amount of platelet in PRP samples was almost four times greater than the platelet amount in peripheral blood samples. More precisely, the average whole blood platelet count was 496, 073±51,273/μl. The average of platelet in PRP samples in group one and two were 1,877,157±604,783/μl and 2,086,945±856,423/μl respectively, which were significantly higher than whole blood.

Conclusion: It can be concluded that both of the methods used for producing autologous PRP show adequate platelet quantity and quality for rabbits.

Keywords: platelet rich plasma, platelet count, modification method, animal models

Introduction

Platelet-rich plasma (PRP), a platelet concentrate made of autologous blood in a small volume of plasma.1,2 PRP contains 4% RBCs, 95% platelets and 1% WBCs.3,4 In reconstructive surgery, slow healing rate or low quality rate of tendons and ligaments as well as massive bone defects are major challenges for the patients.5 Autologous bone grafting is regarded as the gold standard for filling bone defects. However, this method faces several problems such as donor-site morbidity and limited amount of donor bone.6,7 To overcome this challenge, bone regeneration by means of tissue engineering has attracted increasing interest. The notion of tissue engineering is based on three basic parts: scaffolds, cells, and growth factors.8 PRP has greatly attracted attention in scientific society and has been increasingly used for a variety of clinical applications such as orthopedics, sports medicine, dentistry, otolaryngology, neurosurgery, ophthalmology, urology, wound healing, cosmetic, cardiothoracic and maxillofacial surgery.9 PRP therapy has gained broad popularity as a natural alternative to surgery since early 2009, because it is safe, nonsurgical and biological treatment.1 Since PRP is an autologous blood product, it carries no risk of transmissible diseases.8,10 Moreover, PRP can easily be obtained on the day of surgery by means of only two centrifugation steps and simple equipment.

Naturally, after an injury that causes bleeding, platelets are activated and aggregated together near the scar to release their granules contain growth factors which eventually stimulate the inflammatory phase and healing process. As PRP is rich of platelets, it accelerates endothelial, epithelial, and epidermal regeneration, stimulates angiogenesis, increases collagen synthesis, furthers soft tissue healing, reduces dermal scarring, enhances the homeostatic response to injury, and turns the inhibition of wound healing caused by glucocorticoids.11 Moreover, PRP can be added to small bony defects, or to larger defects in combination with grafting material, to increase the rate of bone maturation and improve bone density.12 PRP, contains high concentrations of growth factors like;13 platelet-derived growth factor (PDGF)-AA, -BB,-AB, platelet-derived angiogenesis factor (PDADF), fibroblast growth factor(FGF), transforming growth factor (TGF)-b1 and b-2, insulin like growth factor-1 (IGF-1), connective tissue growth factor(CTGF), platelet derived epidermal growth factor (PDEGF), and platelet factor-4 (PF-4), which these factors have found in α-granules of platelets.14–16 Such growth factors affect the chemotaxis, differentiation, proliferation and synthetic activity of bone cells, which regulates physiological remodeling and fracture healing.17 In addition to growth factors, PRP also releases several bioactive proteins18 that are responsible for attracting macrophages, mesenchymal stem cells and osteoblasts that promote removal of degenerated tissues and also enhance tissue regeneration and healing.19 Several simplified PRP preparation protocols have been proposed to facilitate its clinical application.20–22
Marx et al. suggested that a double-centrifugation method is essential to truly concentrate platelets from autologous blood. Indeed, several fundamental factors must be taken into account while preparing PRP to assure its quality, and consequently, its biological efficacy. It should be noted that the type of protocol used for PRP preparation greatly affects quantitative and qualitative characteristics of the PRP. Some factors such as method of blood collection, type of anticoagulant, relative centrifugal force, method and time of centrifugation and time needed for platelet activation may affect biological quality and efficacy of PRP samples. The aim of the present study was to standardize and modify a new technique for PRP preparation in rabbits. The quantity and quality of platelets in PRP samples of the conventional method, double centrifugation, in this study will be compared with our proposed modified method regarding PRP preparation.

Material and methods

Experimental model

In the present study, ten male New Zealand white rabbits, aged between 9 to 12 months, weighing between 2.5-3 kg were used, which all of them were primarily evaluated in term of CBC parameters. Our study on the experimental animals was conducted in total accordance with the internationally accepted principles for laboratory animal.

PRP preparation

In the first step, rabbits were anesthetized using intramuscular injection of xylazine (3mg/kg) and ketamine (25mg/kg). Blood samples were collected from the jugular vein using a 10ml syringe. Blood samples were transferred to anticoagulant tubes containing 0.35ml of 10% sodium citrate. After that, the blood sample of each animal was divided into two equal amounts of 5ml. Approximately 1ml of whole blood was separated for baseline whole blood analysis. Then, in the standard group blood was initially centrifuged at 160G, for 10 minutes and in the modification group it was first centrifuged at 160G, for 6 minutes at room temperature.

After the first centrifugation, two fractions were observed in each sample: a red lower fraction that consists of packed red blood cells and an upper straw-yellow fraction that contains plasma component (Figure 1). The upper surface of packed red blood cells which called Buffy coat is rich in platelets and leukocytes. Plasma and buff coat were transferred to a new sterile centrifuge tubes. The retained component of blood samples of modification group were centrifuged for two times more at 160G for 2 minutes to obtain more concentrated platelets. Then, in both groups the plasma and Buffy coat was centrifuged for the second round at 400G, for 15 minutes (Figure 2), so two layers were eventually appeared: the upper two thirds of the sample was designated as PPP and was discarded, on the other hand, the lower third was PRP. After that, the platelets were activated by 0.05ml of 10% calcium chloride solution to each 1ml of PRP (Figure 3). It should be noted, in order to accelerate the preparation of PRP gel, it is essential, to put the calcium chloride solution in water bath at 37°C for 10 minutes, just before adding the solution to PRP. From each prepared PRP, 200µL samples were taken to calculate platelet counts with Neubauer chamber (Figure 4). Also, smears were done on all samples in order to see the morphology of the platelets (Figure 5).

Statistical analysis

To compare the difference between the number of platelets in peripheral blood with those of groups one and two, student’s T-test measure was used (P value<0.05).
Standardization and modification techniques of platelet-rich plasma (PRP) preparation in rabbit

The PRP smear for demonstrating the normal morphology and activity. However, the modified protocol caused few changes in platelet morphology. In both groups, a few numerous red blood cells and lymphocytes were seen around platelet aggregates. The average whole blood platelet count was 496,073±62,739/μl and the average of platelet in PRP samples in group one and two were 1,877,157±588,063/μl and 2,086,945±611,026/μl respectively, which were significantly higher than whole blood. It should be noticed that number of platelets was counted with Neubauer chamber using 40x magnifications. The amount of platelet in PRP samples was almost four times greater than that of the peripheral blood samples. More precisely, platelet concentrations of PRP samples in the standard and the modification groups were 380±10% and 420±10% respectively which were higher concentrations of platelets compared to whole blood smears, and platelets demonstrated their original normal morphology and activity. However, the modified protocol caused few changes in platelet morphology. In both groups, a few numerous red blood cells and lymphocytes were seen around platelet aggregates. The average whole blood platelet count was 496,073±62,739/μl and the average of platelet in PRP samples in group one and two were 1,877,157±588,063/μl and 2,086,945±611,026/μl respectively, which were significantly higher than whole blood.

Results

The PRP smears of both groups one and two showed significant growth factors. As the result shows 70% of these growth factors are in rapid activation of platelets and ultimately a mass release of platelets of PRP. Thrombin and CaCl causes the PRP to be dependent on how quickly it is used after activation. Also, variable half-lives of growth factors cause effectiveness of the G as an important factor in the second centrifugation. In addition to the number of centrifugations the force of gravity (G) used in the centrifugation process is one of the important factors. An increase in G may cause higher platelet concentrations. However, it should be noticed that excessive increase the G in the first centrifugation may causes the number of platelets in the Buffy coat to get considerably close to red blood cells. Due to this phenomenon the quantity and efficacy of PRP reduce since during pipe tinging the Buffy coat by sampler, a large number of red blood cells will be pipette, or a portion of platelets will not be pipette, also increasing the G for the second centrifugation may result in prematurely activate the platelets. Efegolu et al. stated a standardized protocol for PRP preparation in rabbits; however the proposed protocol did not consider the effects of G as an important factor in the second centrifugation. The type of anticoagulant used during the process of preparing PRP can activate the premature platelets. EDTA is potentially more damaging than citrate in the preparation of PRP gel since platelets appeared damaged by light microscopy. In a flow cytometric analysis of platelet activation by Nishioka et al. (2002), it was shown that sodium citrate and heparin have activated the minimum platelets, whereas EDTA is potentially more damaging when compared to citrate. EDTA causes significantly higher platelet activation but there is not any significant occurrence of platelet aggregation and release of intracellular constituents. Current knowledge suggests that citrate should be the anticoagulant of choice to obtain PRP for in vivo applications.

As the growth factors have short half-lives in order to obtain the greatest effectiveness they should be activated just prior to injection. Also, variable half-lives of growth factors cause effectiveness of the PRP to be dependent on how quickly it is used after activation. Thrombin and CaCl, are used as clotting agents to activate the platelets of PRP. It has been shown that thrombin can result in rapid activation of platelets and ultimately a mass release of growth factors. As the result shows 70% of these growth factors are}

Discussion

As stated by Marx et al., platelets damaged by the protocol used for preparing PRP will release premature growth factors. Consequently, the resulting outcome may be not satisfying. According to the two different protocols, the effects of the protocol to prepare PRP on the quality and quantity of platelets in PRP samples were evaluated in the present study through platelet smear analysis. Smears were officially accepted to analyze many parameters that are revelatory to platelet function, such as changes in morphology, size, staining specifications, degree of activation and clump formation. A double-centrifugation technique should be applied to truly concentrate platelets from autologous blood. On the other hand, low platelet concentration is caused by a single spin, that it would produce a mixture of PRP and PPP which will not be the true PRP.

Nagata et al. attempted to determine the effectiveness of two protocols for PRP preparation in rabbits and argued that double-centrifugation cause higher platelets concentration in PRP. In our knowledge, several fundamental factors influence on both quantity and quality of PRP including the force of gravity (G), the type of the anticoagulant used, the type of clotting and activating agent, the number of platelets in donor’s blood and PRP, and results of clinical applications. In addition to the number of centrifugations the force of gravity (G) used in the centrifugation process is one of the important factors. An increase in G may cause higher platelet concentrations. However, it should be noticed that excessive increase the G in the first centrifugation may causes the number of platelets in the Buffy coat to get considerably close to red blood cells. Due to this phenomenon the quantity and efficacy of PRP reduce since during pipe tinging the Buffy coat by sampler, a large number of red blood cells will be pipette, or a portion of platelets will not be pipette, also increasing the G for the second centrifugation may result in prematurely activate the platelets. Efegolu et al. stated a standardized protocol for PRP preparation in rabbits; however the proposed protocol did not consider the effects of G as an important factor in the second centrifugation. The type of anticoagulant used during the process of preparing PRP can activate the premature platelets. EDTA is potentially more damaging than citrate in the preparation of PRP gel since platelets appeared damaged by light microscopy. In a flow cytometric analysis of platelet activation by Nishioka et al. (2002), it was shown that sodium citrate and heparin have activated the minimum platelets, whereas EDTA causes significantly higher platelet activation but there is not any significant occurrence of platelet aggregation and release of intracellular constituents. Current knowledge suggests that citrate should be the anticoagulant of choice to obtain PRP for in vivo applications.

As the growth factors have short half-lives in order to obtain the greatest effectiveness they should be activated just prior to injection. Also, variable half-lives of growth factors cause effectiveness of the PRP to be dependent on how quickly it is used after activation. Thrombin and CaCl, are used as clotting agents to activate the platelets of PRP. It has been shown that thrombin can result in rapid activation of platelets and ultimately a mass release of growth factors. As the result shows 70% of these growth factors are significantly higher than platelet concentrations of the peripheral blood samples; whereas, there was no significant difference between the number of platelets in the standard group and the modification group.

Citation: Maghsoudi O, Abarkar M, Anvar SA. Standardization and modification techniques of platelet-rich plasma (PRP) preparation in rabbit. Int Clin Pathol J. 2015;1(2):29-33. DOI: 10.15406/icpjl.2015.01.00007
released within 10 minutes and nearly 100% within 1 hour. Also, the use of bovine thrombin has unfortunately been associated with the development of antibodies.\textsuperscript{35,36} Whereas, platelet gel is formed by using CaCl\textsubscript{2}, the growth factors release can be slowed and released over 7 days.\textsuperscript{37} According to results, in the ant coagulated state and placed on a sterile surgical table, PRP can be remained sterile and the concentrated platelets viable for up to 8 hours.\textsuperscript{38} It is not a valid idea that higher number of platelets necessarily accelerates tissue healing because an excessively concentrated PRP has negative effects on wound healing.\textsuperscript{39,40} It is necessary that a “therapeutic PRP” show approximately one million platelets per micro liter in humans. Thus, in order to consider a PRP as “therapeutic PRP,” it should have a platelet concentration of at least 300 to 400% greater than that of the whole blood.\textsuperscript{41} Platelet concentrations of less than 10\textsuperscript{7}/\mu l was not reliable for enhancing wound healing.\textsuperscript{38} Discarding the upper thirds of the sample after second centrifugation may result in more highly concentrated platelets of PRP.\textsuperscript{39} As suggested by Efeoglu et al.\textsuperscript{42} the platelet concentration may be higher in a small volume of plasma than in a greater volume of plasma. PRP has acidic pH.\textsuperscript{43} and also is rich in leukocyte. Furthermore, PRP results in chemotaxis and migration of cells such as WBCs. Accordingly, it might be claimed that PRP actually inhibits bacterial growth.

\section*{Conclusion}
Whereas the average of platelets in PRP samples of both groups was approximately four times more than the average of platelets in whole blood, there was no significant difference between the number of platelets in the standard group and the modification group. Therefore it can be concluded that both of the methods used for producing autologus PRP show adequate platelet quantity and quality for rabbits. However, the modified protocol caused partly changes in platelet morphology.

\section*{Acknowledgements}
None.

\section*{Conflict of interest}
The author declares no conflict of interest.

\section*{References}
1. Everts PA, Knape JT, Weibrich G. Platelet-rich plasma and platelet gel: a review. J Euro Corp Technol. 2006;38(2):174–187.
2. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofacial Surg. 2004;62(4):489–496.
3. Dhillon RS, Schwartz EM, Maloney MD. Platelet-rich plasma therapy: future or trend? Arthritis Res Ther. 2012;14(4):219.
4. Malik AH, Tabasum R, Ahmad M, et al. Autogenous platelet rich plasma in healing of bone defects. World J Med Sci Res. 2013;1(5):82–84.
5. Sutter W. Platelet Rich Plasma. Vet-Stem Cell Therapy; 2007. p. 1–8.
6. Arrington ED, Smith WJ, Chambers HG, et al. Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res. 1996;(329):300–309.
7. Damien C, Parsons R. Bone graft and bone graft substitutes: review of current technology and applications. J Appl Biomater. 1990;2(3):187–208.
8. Kasten P, Vogel J, Geiger F, et al. The effect of platelet-rich plasma on healing in critical-size long-bone defects. Biomaterials. 2008;29(29):3983–3992.
9. Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review. Curr Rev Musculoskelet Med. 2008;1(3-4):165–174.
10. Smith RG, Gassmann CJ, Campbell MS. Platelet-rich plasma: properties and clinical applications. The Journal of Lancaster General Hospital. 2007;2(2):73–78.
11. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plastic Reconstr Surg. 2004;114(6):1502–1508.
12. Creaney L, Hamilton B. Growth factor delivery methods in the management of sports injuries: the state of play. Br J Sports Med. 2008;42(5):314–320.
13. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost. 2011;105(Suppl 1):13–33.
14. Rozman P, Bolta Z. Use of platelet growth factors in treating wounds and soft-tissue injuries. Acta DermatoVenereol Alp Pannonica Adr. 2007;16(4):156–165.
15. Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of sites for implants. Int J Oral Maxillofac Implants. 1999;14(4):529–535.
16. Landesberg R, Roy M, Glickman RS. Quantification of growth factor levels using a simplified method of platelet-rich plasma gel preparation. J Oral Maxillofac Surg. 2000;58(3):297–300.
17. Messora MR, Nagata MJH, Furlaneto FAC, et al. A standardized research protocol for platelet-rich plasma (PRP) preparation in rats. RSBO. 2011;8(3):299–304.
18. Nagata MJ, Messora MR, Furlaneto FA, et al. Effectiveness of two methods for preparation of autologous platelet-rich plasma: an experimental study in rabbits. Eur J Dent. 2010;4(4):395–402.
19. Sonleitner D, Huemer P, Sullivan DY. A simplified technique for producing Platelet-rich plasma and platelet concentrate for intraoral bone grafting techniques: A technical note. Int J Oral Maxillofac Implants. 2000;15(6):879–882.
20. Tamimi FM, Montalvo S, Tresguerres I, et al. A comparative study of 2 methods for obtaining platelet-rich plasma. J Oral Maxillofac Surg. 2007;65(6):1084–1093.
21. Dugrillon A, Eichler H, Kern S, et al. Autologous concentrated platelet-rich plasma (cPRP) for local application in bone regeneration. Int J Oral Maxillofac Surg. 2002;31(6):615–619.
22. Efeoglu C, Delen AY, Ertürk S. A modified method for preparing platelet-rich plasma: an experimental study. J Oral Maxillofac Surg. 2004;62(11):1403–1407.
23. Halmay D, Sántonyi P, Vajdovich P, et al. Morphological evaluation of canine platelets on Giemsa- and PAS-stained blood smears. Acta Vet Hung. 2005;53(3):337–350.
24. Marx RE, Carlson ER, Eichstaedt RM, et al. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol. 1998;85(6):638–646.
25. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofacial Surg. 2004;62(4):489–496.
26. Man D, Plosker H, Winland-Brown JE. The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery. Plast Reconstr Surg. 2001;107(1):229–237.
27. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10(4):225–228.
28. Macey M, Azam U, McCarthy D, et al. Evaluation of the anticoagulants

\section*{Citation}
Maghsoudi OA, Abarkar M, Anvar SA. Standardization and modification techniques of platelet-rich plasma (PRP) preparation in rabbit. Int Clin Pathol J. 2015;1(2):29–33. DOI: 10.15406/icpjl.2015.01.00007
EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 hematology system. Clin Chem. 2002;48(6 Pt 1):891–899.

29. Lozada JL, Caplanis N, Proussefs P, et al. Platelet-rich plasma application in sinus graft surgery: Part 1, Background and processing techniques. J Oral Implantol. 2001;27(1):38–42.

30. Landesberg R, Roy M, Glickman RS. Quantification of growth factor levels using a simplified method of platelet-rich plasma gel preparation. J Oral Maxillofac Surg. 2000;58(3):297–300.

31. Sonnleitner D, Huemer P, Sullivan DY. A simplified technique for producing platelet-rich plasma and platelet concentrate for intraoral bone grafting techniques: A technical note. Int J Oral Maxillofac Implants. 2000;15(6):879–882.

32. Snyder EL, Calhoun BC. Topical platelet growth factor therapy: Of lotions and potions. Transfusion. 2001;41(10):1186–1189.

33. Whitman DH, Berry RL, Green DM. Platelet gel: An autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J Oral Maxillofac Surg. 1991;55(11):1294–1299.

34. Zimmermann R, Jakubietz R, Jakubietz M, et al. Different preparation methods to obtain platelet components as a source of growth factors for local application. Transfusion. 2001;41(10):1217–1224.

35. Foster TE, Puskas BL, Mandelbaum BR, et al. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009;37(11):2259–2272.

36. Graziani F, Ivanovski S, Cei S, et al. The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. Clin Oral Implants Res. 2006;17(2):212–219.

37. Yamaguchi, Terashima H, Yoneyama S, et al. Effects of platelet-rich plasma on intestinal anastomotic healing in rats: PRP concentration is a key factor. J Surg Res. 2012;173(2):258–266.

38. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10(4):225–228.

39. Kececi Y, Ozu S, Bilgir O. A cost-effective method for obtaining standard platelet-rich plasma. Wounds. 2014;26(8):232–238.